Looking to expand its glycogen synthase kinase-3 beta (GSK-3beta) inhibitor program, Northwestern University spinout Actuate Therapeutics Inc. has secured $21.7 million in a series B round led by Kairos Ventures. Defta Partners and Tech Coast Angels, with existing investor Bios Partners also participated in the round.